for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Co-Diagnostics Inc

CODX.O

Latest Trade

7.17USD

Change

-0.45(-5.91%)

Volume

1,133,684

Today's Range

6.81

 - 

7.45

52 Week Range

0.69

 - 

21.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.62
Open
7.42
Volume
1,133,684
3M AVG Volume
245.68
Today's High
7.45
Today's Low
6.81
52 Week High
21.75
52 Week Low
0.69
Shares Out (MIL)
25.39
Market Cap (MIL)
208.16
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Co-Diagnostics Completes Successful Clinical Evaluation Required For FDA Emergency Use Authorization

Co-Diagnostics - FDA Policy Change To Allow Rapid Domestic Expansion Of Co-Diagnostics Covid-19 Test

Precheck Health Services Enters Into Distribution Agreement With Co-Diagnostics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Co-Diagnostics Inc

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Contact Info

4049 S Highland Dr

SALT LAKE CITY, UT

84124-1664

United States

+1.801.2789769

http://codiagnostics.com/

Executive Leadership

Dwight H. Egan

Chairman of the Board, President, Chief Executive Officer

Reed L. Benson

Chief Financial Officer, Secretary

Brent Satterfield

Chief Scientific Officer

Eugene Durenard

Independent Director

Edward L. Murphy

Independent Director

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.500

2019

-0.360

2020(E)

0.127
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,775.84
Price To Book (MRQ)
42.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-318.25
Return on Equity (TTM)
-196.43

Latest News

Latest News

BRIEF-Co-Diagnostics Completes Successful Clinical Evaluation Required For FDA Emergency Use Authorization

* CO-DIAGNOSTICS, INC COMPLETES SUCCESSFUL CLINICAL EVALUATION REQUIRED FOR FDA EMERGENCY USE AUTHORIZATION

BRIEF-Co-Diagnostics JV Cosara First Indian Company To Receive License For Covid-19 Diagnostic

* CO-DIAGNOSTICS JV COSARA FIRST INDIAN COMPANY TO RECEIVE LICENSE FOR COVID-19 DIAGNOSTIC

Co-Diagnostics says new FDA policy to help expand use of COVID-19 test

Co-Diagnostics Inc said on Tuesday the U.S. Food and Drug Administration's new policy to expand the availability of COVID-19 tests would allow the medical test maker's tests to be distributed to a wide array of U.S. labs.

Co-Diagnostics says new FDA policy to help expand use of COVID-19 test

Co-Diagnostics Inc said on Tuesday the U.S. Food and Drug Administration's new policy to expand availability of COVID-19 tests will allow the medical test maker's tests to be distributed to a wide array of U.S. labs.

BRIEF-Co-Diagnostics - FDA Policy Change To Allow Rapid Domestic Expansion Of Co-Diagnostics Covid-19 Test

* FDA POLICY CHANGE TO ALLOW RAPID DOMESTIC EXPANSION OF CO-DIAGNOSTICS COVID-19 TEST

BRIEF-Precheck Health To Exclusively Distribute Coronavirus Covid-19 Test In Ecuador For Co-Diagnostics

* PRECHECK HEALTH TO EXCLUSIVELY DISTRIBUTE CORONAVIRUS COVID-19 TEST IN ECUADOR FOR CO-DIAGNOSTICS, INC.

BRIEF-Precheck Health Services Enters Into Distribution Agreement With Co-Diagnostics

* PRECHECK HEALTH SERVICES - ON MARCH 9, 2020, ENTERED INTO DISTRIBUTION AGREEMENT WITH CO-DIAGNOSTICS INC - SEC FILING

BRIEF-Co-Diagnostics Inc Reports Additional Demand For Coronavirus Test Shipments

* CO-DIAGNOSTICS, INC. REPORTS ADDITIONAL DEMAND FOR CORONAVIRUS TEST SHIPMENTS

BRIEF-Co-Diagnostics Inc To Provide Covid-19 Tests To US CLIA Labs Following FDA Policy Change

* CO-DIAGNOSTICS, INC. TO PROVIDE COVID-19 TESTS TO US CLIA LABS FOLLOWING FDA POLICY CHANGE

BRIEF-Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-The-Market

* CO-DIAGNOSTICS ANNOUNCES $4.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Co-Diagnostics Receives CE Mark For Novel Coronavirus Test

* CO-DIAGNOSTICS, INC. RECEIVES CE MARK FOR NOVEL CORONAVIRUS TEST

BRIEF-Co-Diagnostics Completes Submission Of CE Marking Registration For COVID-19 Coronavirus Test

* CO-DIAGNOSTICS COMPLETES SUBMISSION OF CE MARKING REGISTRATION FOR COVID-19 CORONAVIRUS TEST

BRIEF-Co-Diagnostics To Present Its Rapid Response To New Coronavirus In Washington D.C. Conference

* CO-DIAGNOSTICS, INC. TO PRESENT ITS RAPID RESPONSE TO NEW CORONAVIRUS IN WASHINGTON D.C. CONFERENCE Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-The-Market

* CO-DIAGNOSTICS ANNOUNCES $10.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Gilead working with China to test Ebola drug as new coronavirus treatment

Gilead Sciences Inc <GILD.O> said on Friday it provided its experimental Ebola therapy for use in a small number of patients with the coronavirus that has killed over 200 so far in China and is working with the country's authorities to set up a study.

BRIEF-Co-Diagnostics Announces Construction Update At Facility In India

* CO-DIAGNOSTICS, INC. ANNOUNCES CONSTRUCTION UPDATE AT JV MANUFACTURING FACILITY IN INDIA

BRIEF-Co-Diagnostics Inc Announces Positive Results From Co-Primers Technology In Multiplex Tests For SNP Detection

* CO-DIAGNOSTICS INC ANNOUNCES POSITIVE RESULTS FROM CO-PRIMERS™ TECHNOLOGY IN MULTIPLEX TESTS FOR SNP DETECTION Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics Enters Into Lease For Upgraded Laboratory Facility In Salt Lake City

* CO-DIAGNOSTICS - ENTERS INTO LEASE FOR BIOLOGICAL SAFETY LEVEL 2 LABORATORY FACILITY IN SALT LAKE CITY, UTAH

BRIEF-Co-Diagnostics to sign purchase agreement with Medcis Pathlabs

* Co-Diagnostics, Inc to sign purchase agreement with Medcis Pathlabs

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up